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Hp eradication: about a large therapeutic trial in Linqu (China)
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Sir,
It is well known that gastric cancer (GC) is the second leading
cause of cancer deaths in the world. In China, there is conside-
rably geographic variation with very high rates in northern and the
central parts of the country. In Linqu County/Shandong province,
one of the highest rates not only in China but in the world is found,
in 1980 – 1982 the age adjusted (world standard) death rate of
GC was 70/100.000 in males and 25/100.000 in females. A
recent study indicated that the crude mortality rates remained at
this level since then. GC accounts for 40% of cancer deaths in
Linqu County.
We describe shortly a randomized, controlled trial among
200.000 adult participants to prevent GC in Linqu County. The
main target of this large population based intervention trial is to
assess whether GC can be prevented by eradication of
Helicobacter pylori (Hp) in the high-risk population. Secondary
aims include the identification of genetic and serologic risk factors
for Hp associated GC and neoplastic lesions.
There is growing evidence that treating Hp infection may lead to
a reduced risk of subsequent GC. Combined data from previous
trials seems to indicate this assumption. However, the protective
effect is suggestive but not statistically significant. Thus a large
population-based randomized trial is needed to prove that eradi-
cation of Hp reduces GC incidence rate.
This new study was launched in March 2011 – is a collaborative
study between the Peking University School of Oncology (PUSO),
the International Digestive Cancer Alliance (IDCA), Technische
Universitaet Muenchen and Charles University (Prague).
We will screen approximately 200.000 residents aged 25 – 54
from 900 villages in Linqu County fulfilling the inclusive and
exclusion criteria. The Hp status will be determined by 13 C-urea
breath test (13C-UBT). We estimate the 140.000 participants will
be positive. These subjects will be enrolled in the intervention
study and randomized for two different antimicrobial treatment
regimens with high or low dosage of omeprazole, tetracycline,
metronidazole and bismuth by villages with 70.000 in each arm.
All participants in both antimicrobial treatment groups will be
followed for at least 10 years to assess the incidence and morta-
lity rates of GC. This study has a power of 90% to determine
whether eradication of Hp can effectively reduce the incidence by
at least 21% at the 0.05 significance level.
The results of this study will have worldwide public health implica-
tions for all countries having a high incidence of GC. The study
has been approved by the Institutional Review Board of PUSO
and collaborating institutions.
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